Ukubuyisela emuva ukuguga: isayensi
Iningi lezinkinga eziphelisa impilo yethu zinezingxenye ezimbili: ukukhuluphala. Ngokukuqala, abacwaningi bangawukhawulela kuzinyoni futhi babuyisele ezinye zezinkomba zayo kumaseli. Akunalutho oluye lwaqinisekiswa ukuthi lubuyisela emuva ukukhuluphala kwabantu, kodwa isayensi iyiqiniso, futhi iyahamba ngokushesha.
Snuupo / Wikimedia Commons (CC BY-SA 4.0)
Kuningi kwembali, abantu bafa bencane ngenxa yezifo, izilonda kanye nokuzalwa. Namhlanje, engxenyeni enkulu yezwe, abantu bafa bekhulu, futhi bafa ngenxa yohlu oluncane lwezifo eziqhubekayo: izifo zenhliziyo, isifo sofuba, i-cancer, ukugula kwengqondo, isifo sikashukela kanye nezinkinga zezinso. Zonke lezi zinkinga zineziguli zayo, izinhlangano ezisiza abantu kanye nezidakamizwa. Kodwa-ke, babelana ngomphumela owodwa obalulekile wokungasebenzi kahle, futhi akuyona ukushaya umsindo, ukudla noma ama-gene. Iminyaka. Isigaba esikhulayo sesayensi, ebizwa ngokuthi i-geroscience, ubuza imibuzo elula: endaweni yokubhekana nesifo ngasinye seminyaka emidala ngokuzimela, singamisa kanjani inqubo yobudala oyenzayo yonke? Le khasi lichaza, ngokucacile futhi ngokuthembekile njengoba sikwaziyo, ukuthi yini okushoyo lo cwaningo, yini engashoyo, nokuthi yini engenza siqonde ngayo.
Kungani ukukhuluphala kuyisihluthulelo sezinkinga eziningi eziqhubekayo
Thola noma yisiphi isifo esivamile esiqhubekayo ngobudala futhi isitayela esifanayo sivela: kuncane kubantu abadala abancane, bese kukhuphuka ngokuqinile ngeminyaka eminingi. E-United States ngo-2025, cishe i-0.5% yabantu abadala abaneminyaka engu-18 kuya ku-44 babevele betholakele ukugula kwenhliziyo; phakathi kwabantu abaneminyaka engama-75 nangaphezulu kwaba yi-19%. Noma yisiphi isifo somdlavuza: amaphesenti angama-2 ku-33%. isifo sofuba: 6% ku-53% (I-NCHS, i-NHIS 2025). Ucwaningo olusha lwesifo sikashukela luyakhula kusuka kumaphesenti angama-236 kumuntu ngamunye oneminyaka engu-100,000 ngonyaka phakathi kweminyaka engama-40 no-44 kuya kumaphesenti angama-2,400 phakathi kweminyaka engu-80 no-84 (I-NCI SEER). Ingxenye yabantu abaphila ne-dementia iphindaphindwa njalo eminyakeni emihlanu kuya kwezintathu ngemuva kweminyaka engu-65, ifinyelela cishe kumuntu oyedwa kuthathu eneminyaka engama-90 nangaphezulu (Manly et al., 2022).
Kulwazi oluvela e-US ngezansi, isifo senhliziyo esibangelwa yi-coronary heart disease sivame kakhulu ngamaphesenti angama-38 kubantu abaneminyaka engu-75 nangaphezulu kunalabo abaneminyaka engu-18 kuya ku-44. Lokhu kuyisizathu sokuthi iqembu labacwaningi abahamba phambili bachaza ukukhuluphala njengo “umphumela omkhulu wengozi yengxenye enkulu yezifo eziqhubekayo” futhi baphakamisa ukuthi ukwelashwa kokukhuluphala kungalibazisa abaningi kubo (Kennedy et al., 2014). Le yi-geroscience hypothesis. Kunemiphumela esebenzayo. Ukuvimbela isifo esisodwa seminyaka edlulele kungeza impilo encane, ngoba abanye belinde: abantu abagcinwe emgodini wenhliziyo baqhubeka nokulwa ne-cancer, i-dementia noma ukushaya kwenhliziyo eminyakeni eminingana ngemuva. Ukuncipha kokukhuluphala kuzozisusa zonke emuva ngasikhathi sinye.
Abacwaningi bezomnotho bazama ukubeka inzuzo kulolu daba. Ucwaningo lwe-2013 e-US lwathola ukuthi ukulibazisa okuncane ekukhululeni kuzongeza cishe iminyaka engu-2.2 yokuphila, ngaphezu kwazo zonke ezinempilo, okungukuthi, cishe ama- $ 7.1 trillion eminyakeni eyi-50 (Goldman et al., 2013). Ucwaningo lwe-2021 lulinganisela ukuthi ukuncipha kokukhuluphala okunembile ukufaka unyaka owodwa wokuphila olindelekile kuzobiza i- $38 trillion to the US, and ten years $367 trillion (Scott, Ellison and Sinclair, 2021). Lezi zinhlobo zikhiwa ngezinqumo, kodwa zibonisa ukuthi kungani izinhlangano nezitshalizimali zinikela ingqalelo.
Iqiniso elihamba kancane: izimpawu zokukhuluphala
Ukukhuluphala akuyona indlela eyodwa kodwa eminingi, ivela ndawonye futhi isizana. Ngo-2013 iqembu eliholwa nguCarlos López-Otín lazihlanganisa zibe ngama- izimpawu zokukhuluphala, futhi ngo-2023 lawungeza uhlu lwaba mahlanu (López-Otín et al., 2013; López-Otín et al., 2023). Ngegama elilula:
- Isimo esingazinzi se-genomic: ukulahleka kwe-DNA kwenziwa ngokushesha kunalokho okulungiswe.
- I-Telomere attrition: ama-caps avikelayo emaphethelweni e-chromosomes agqoke phansi.
- Izinguquko ze-epigenetic: amaphawu ekhemikhali ashintsha i-jenethi futhi aphume emgodini wabo omusha.
- Ukulimala kwe-proteostasis: amaprotheni aphindwe ngokungalungile futhi ahlanganisene.
- I-macroautophagy ekhubazekile: iseli lendlela yokuvuselela lihamba kancane.
- Ukwaziswa kwezinto eziphilayo okungemthetho: amasignali okukhula njenge-mTOR ne-insulin ahlala esebenza uma ukulungisa kungcono.
- Mitochondrial dysfunction: ama-power stations eselula akhiqiza amandla aphansi futhi akhiqize izinto ezibulalayo.
- Cellular senescence: amaseli afile ayeka ukuhlukaniswa kodwa a refuse ukufa, futhi akhipha izibonakaliso zokuvuvukala.
- Isitho sokuqala sokulahlekelwa amandla: ama-reserve asiza ukubuyisela izicubu awela phansi.
- Ukuxhumana phakathi kweselula okushintshiwe: amasignali phakathi kweziseli nezinto eziphilayo ahamba kabi.
- I-chronic inflammation: ukuvuvukala okuphansi, okungapheli, ngamanye amaxesha kubizwa ngokuba “ukuvuvukala”.
- Dysbiosis: ukulinganisela kwamagciwane ezindaweni ezincane.
Yonke indlela kule khasi ibeka emgqeni eyodwa noma ngaphezulu yalezi zibonakaliso. Izimo ze-hallmark zidinga: kufanele ivele ngobudala, ukukhawulela kufanele kusheshise ubudala, futhi ukukhawulela kufanele kusheshise ubudala. Ukuhlolwa kokugcina kulapho ithemba livela khona, ngoba lezi zinhlelo eziningi, abacwaningi bakwenzele izilwane.
Siqiniseke kangakanani? Isikali seqiniso
Igama “anti-ageing” lifaka konke kusuka emikhubani eqinisekisiwe emazigidini abantu kuya kumaqiniso ahlolwe kucwaningo lwegundane elilodwa. Ukuzigcina zihlukene, yonke indlela kule khasi ifaka enye yezinhlamvu ezine:
- Iqinisekisiwe kubantu: izifundo ezinkulu zomuntu kanye nezilingo ezingenakubalwa zibonisa ukuthi kunezifo ezincane nezifa.
- Izifundo ezimangazayo zomuntu: izifundo ezihamba phambili kubantu zibonisa imiphumela ebonakalayo, kodwa asikho ngokukhuluphala ngokwaso.
- Inamandla ezilwaneni: iziphetho eziphindaphindwayo, eziqinile ezilwaneni; isivivinyo somuntu esincane, esixutshwe noma esiqala nje.
- Early noma ecabangayo: iphutha, ezingqubuzana noma isivivinyo-yesibili ibufakazi, noma izilingo zabantu kuze kube manje kakhulu ngaphandle inzuzo ecacile.
Ukusho ngokucacile: akukho lutho kulekhasi elizobonisa ukuthi lihamba kancane noma libuyisela emuva ukukhuluphala kwabantu bonke. Akunamithi, isithako noma ukwelashwa kwe-gene okugunyazwe ukuphatha ukukhuluphala nakweyiphi na indawo emhlabeni. Ngakho kungani abacwaningi abakhulu bethakazelisa? Ngenxa yokuthi eminyakeni eyisithupha eyedlule akukho muntu ongakwazi ukudlulisa impilo yenyamakazi ejwayelekile ngemithi, futhi manje izidakamizwa eziningi zikwenza, ezivivinyweni eziqinile ezitholakala emalabhorethri amaningi ngasikhathi sinye; ngoba amaseli adala angasetshenziswa ukuziphatha njengezingane futhi ku-dish futhi, kwezinye izitho, ezinhlanzini eziphilayo; futhi ngenxa yokuthi izifundo zomuntu wokuqala ezibhekiswe kwi-biology yokukhuluphala, hhayi esifo esisodwa, manje sezihamba phambili. Ukuhamba ukusuka kwigundane kuye kumuntu kuhlala isikhathi eside, futhi ama-imibono athembisayo amaningi alahlekelwa yisikhathi. Kodwa indlela icacile.
Ukulinganisa izithako ezibalulekile: i-mTOR ne-rapamycin
Izinga lemibiko: lithembisa ukucwaswa kwabantu
Iyini. Isiseli ngasinye sidinga ukucabanga ukuthi sizokhula noma sizolungisa ngokwaso. I-protein complex ebizwa nge mTOR (injongo ye-rapamyin) yenza lo msindo: lapho ukudla nokuthuthukiswa kwezimpawu kuningi, i-mTOR ithi “ukukhula”; uma zincane, ithatha izinqumo futhi iseli lishintsha ukulondoloza, kufaka phakathi ukuphindaphinda izingxenye zayo ezisetshenziswayo ngo-autophagy. Ngokuphila kwethu okukhulu, i-mTOR ivame ukuhlala ixhunywe kakhulu kunalokho okulungile kithi. Ukuyivala ngezansi kuyinye yezindlela eziqhubekayo kakhulu zokudlulisa impilo e-yeast, amagciwane, izimvu kanye nezinhlanzi.
i-Rapamycin imithi evimbela mTOR. Kutholakala engxenyeni yemvelo yaseRapa Nui (isiqhingi sase-Easter), eyaziwa ngokuthi yi-Streptomyces hygroscopicus, lapho ikhiqizwa khona yibhaktheriya.Vézina, Kudelski noSehgal, 1975). Isetshenziswa iminyaka eminingana ezindaweni eziphezulu zokuvimbela umzimba ekubekezeleleni ama-organs afakwe.

Kuzilwane. Ngo-2009 i-US National Institute on Aging’s Interventions Testing Program, ehlola amakhemikhali ezinyangeni ezihlukahlukene zezinja ezihlukile ezimbonini ezintathu ngasikhathi sinye, yashicilela ukuthi i-rapamycin yandisa impilo ngisho nasekuqala kunikezwa eminyakeni engu-600 yobudala, ngemuva kokuphila kwengane. Ngobude obunjalo, ukulindeleka kokuphila kwakhuphuka ngo 28 ngephesenti kubantu besifazane na38 ngephesenti kubantu abadala (Harrison et al., 2009). Ku dose ephezulu yaqala ephakathi neminyaka, umthamo wempilo wakhula ngo-23% kubantu abadala kanye no-26% kubantu besifazane (Miller et al., 2014). I-Rapamycin iyimithi emibili kuphela esebenza kahle emidlalweni emithathu, futhi ihlala iyimithi enamandla kakhulu yokuthuthukisa impilo yezilwane ezifuywayo.
Kubantu. Ubufakazi bomuntu buncane kodwa bukhona. Kulesi sifundo esihlobene nabesifazane abakhulu, amaviki ayisithupha we-everolimus, ohlobo olusha lwe-rapamycin, wathuthukisa ukuphendula kwegciwane lesifo sofuba ngo-20% (Mannick et al., 2014), futhi isifundo sesikhathi esizayo sokuxubana okuphathelene nokuncipha kwezifo ngonyaka olandelayo (Mannick et al., 2018). Kodwa-ke, isikhashana esiningi 3 sokuhlolwa kwemithi efana nale, kubantu abangaphezu kuka 1,000 abadala, asikho ukwehluleka kokugula okuphefumulayo (Mannick et al., 2021). Ukuhlolwa kwe-PEARL kwanikeza abantu abadala abaphilile amadosi aphansi eviki ngalinye we-rapamycin iminyaka engu-48. Akushintshi ukuhlolwa kwayo okuyinhloko, i-visceral fat, futhi izinzuzo zayo zangaphandle zazifana ne-placebo; ezinye izifundo ezilandelayo, ezinjengemisipha encane kubantu besifazane abathatha umthamo ophezulu, zithuthukiswe (Moel et al., 2025). Ukuhlolwa kwe-2024 kwezifundo ezingu-19 akubonisi izimo ezingathandeki kubantu abasempilweni, kodwa kunezifo eziningi nezilonda zegazi eziphezulu kubantu abanesifo esiphathelene nobudala (Lee, Kuerec neMaier, 2024).
Ingozi. Esikhathini sokufaka izidakamizwa, i-rapamycin icindezela uhlelo lokuzivikela futhi iletha izixwayiso mayelana nokutheleleka okubi kanye nezinye izifo zesifo sikashukela. Ubuhlungu bemilomo, ukukhula kwe-cholesterol ne-triglycerides, ukuvuvukala okukhawulelwe nokukhishwa kwamagciwane yimiphumela emibi ebhalwe ngezansi (US FDA sirolimus label). Kuzinhlanzi, ukusetshenziswa okude kwenza ukuthi kube nokumelana ne-insulin (Lamming et al., 2012). Abacwaningi manje behlola izidakamizwa eziphansi neziqhubekayo, kanye nemithi entsha evimbela kuphela ingxenye ye-mTOR exhunywe nokuphila isikhathi eside.
Senolytics: ukususa amaseli “ama-zombie”
Izinga lemibiko: linamandla emithonjeni yenyama
Iyini le? Uma iseli lilahlekile, lingangena ezweni elibizwa ngokuthi yi-senescence: liyeka ukuhlukaniswa, okuvimbela ukugula ngenhliziyo, kodwa alifa. Amaseli akhula ngokukhululwa. Kunzima kakhulu, bakhipha i-cocktail yezimpawu zokuvuvukala, i-senescence-associated secretory phenotype (SASP), ebangela ukulahlekelwa amaseli asebenzayo abhekene nawo (Coppé et al., 2008). Senolytics yimithi eyenziwe ukubulala amaseli asesikhathini ngokukhetheka.

Kuzilwane. Ngo-2011, abacwaningi bathuthukise izinja ngezinto eziphilayo ukuze iziseli zabo ezincane zingasuswa uma kudingeka. Ukuzisusa kuzokuvimbela ukulahlekelwa okuhlobene nobudala ezindaweni ezinama-fat, amathambo kanye nemehlo (Baker et al., 2011). Ezinhlanzi ezijwayelekile, ukususa lezi zingxenye kusuka eminyaka emiphakathini yandisa isikhathi sokuphila esiphakathi ngo-24 kuya ku-27% (Baker et al., 2016). I-senolytic drug combination yokuqala, dasatinib plus quercetin, yatholakala ngo-2015 (Zhu et al., 2015). Inikezwa izimpumputhe ezidala kakhulu, yathuthukisa umsebenzi wemvelo futhi yandisa isikhathi sokuphila esisele ngephesenti le-36 (Xu et al., 2018). Fisetin, i-compound ejwayelekile etholakala ezindaweni ze-strawberries, yandise isikhathi sokuphila uma inikezelwa izimpumputhe ezidala (Yousefzadeh et al., 2018).
Kubantu. Iziphetho zomuntu wokuqala zincane futhi zihlanganisiwe. Kubantu abangu-14 abanesifo sofuba, isifo senhliziyo esibuhlungu, amaviki amathathu edasatinib kanye ne-quercetin athuthukise ubude bokuhamba nokukhawulela, kepha hhayi umsebenzi wesifo sofuba, kuphenyo olungaba yiqembu le-placebo (Justice et al., 2019). In nine people with diabetic kidney disease, the drugs reduced senescent cells in fat and skin and lowered inflammatory signals in the blood (Hickson et al., 2019). Kodwa-ke, empilweni yokuhlolwa okungahleliwe kwabasesilisa abaneminyaka engu-60 ubudala, amaphilisi awathuthukisi ithambo lonke; abesifazane kuphela abaneselula ezincane kakhulu zabonakala zithola inzuzo (Farr et al., 2024). Kulesi sigaba, i-Alpha GPC isebenza njenge-antidepressant futhi ingasiza ukuvimbela ukukhula kwe-Alzheimer’s. I-dasatinib ifinyelele ebusweni bengqondo kodwa i-quercetin ayizange (Gonzales et al., 2023). Izifundo ezinkulu zefisetin e-Mayo Clinic ziqhubeka (ClinicalTrials.gov NCT03675724).
The first company built around senolytics, Unity Biotechnology, tested an eye injection, UBX1325 (foselutoclax), for diabetic eye disease. Ngemuva kokuqala kwenqubo ekhuthazayo, isigaba esincane se-2 sokubhekana nesimo esijwayelekile sathola ukuthi asikho isizathu sokuqala (Unity Biotechnology, 2025), futhi inkampani yasuswa ngemuva kwalokho ngonyaka (SEC filing, 2025).
Ingozi. I-dasatinib iyimithi yokugoma isifo sikashukela enamandla okulimaza, kufaka phakathi ukulahlekelwa ushukela wegazi. Amaseli akhula ngokushesha anemisebenzi ebalulekile, isibonelo ukuvuvukala kwesikhumba, ngakho-ke ukuwasusa akuyona into engaphephile.
NAD+, NMN ne-NR
Izinga lemibiko: eliqaleni noma elisha
Yini. I-NAD+ iyimolekyuli encane edingekayo yiseli ngalinye ukushintsha ukudla ibe amandla nokubuyisela i-DNA. Amanqanaba ayo aphansi ngobudala emisipha eminingi. Izinhlanganisela ezimbili eziphambili ukuthi umzimba ungashintsha ibe yi-NAD +, nicotinamide mononucleotide (NMN) ne-nicotinamide riboside (NR), zithengwa njengezithako.
Kuzilwane. Kuzinhlanzi, unyaka we-NMN emanzini okudla wavimbela izinguquko eziningi eziphathelene nobudala, kufaka phakathi ukuthuthukiswa kwesisindo nokuncipha kokusetshenziswa kwamandla (Mills et al., 2016), futhi i-NR yathuthukisa umsebenzi we-mitochondrial neseli le-stem kanye nokuphila okude kakhulu kwezinhlanzi ezindala (Zhang et al., 2016). Kodwa lapho i-Interventions Testing Program ihlola i-NR ngemodeli yayo eqinile, ayisebenzisi isikhathi sokuphila kunoma yisiphi isifazane (Harrison et al., 2021).
Kubantu. NR ne-NMN ziphakamisa ngokunethezeka i-NAD + emlonyeni (Martens et al., 2018). Inqubo engcono kakhulu eyaziwayo inikeza i-NMN kubantu besifazane abangu-25 abane-prediabetes iminyaka emihlanu: ukusabela kwe-insulin yamathambo kuthuthukiswe ngamaphesenti angama-25, ngenkathi ukushisa kwegazi, ama-fats wegazi kanye nokwakheka kwesikhumba ashintshiwe (Yoshino et al., 2021). Kulesi sifundo esincane sesifo sikaParkinson, i-NR yakhuphula i-NAD engqondweni ngokuphuculwa okuncane kweklinikhi (Brakedal et al., 2022); isifundo esikhulu saqediwe futhi izimpendulo zayo zilindelwe. Izibuyekezo eziqoqa izifundo kuze kube manje zithola ama-supplements aphephile ngesikhathi esincane kodwa cishe akukho inzuzo ecacile ye-glucose yegazi, i-fat yegazi noma imisipha (Zhang et al., 2025; Prokopidis et al., 2025). Okungaboniswe: ukuthi ukunciphisa i-NAD + kunciphisa ukukhuluphala noma kuvimbela noma yiziphi izifo kubantu.
Imithetho. Ku-2022 i-US Food and Drug Administration yathi i-NMN ayikwazi ukuthengwa njengengxenye yokudla ngoba yayifundwa njengotshwala; ngoSepthemba 2025 yashintsha lokho (FDA, 2025). Ukuhlala emakethe akusho lutho mayelana nokuthi imikhiqizo isebenza kanjani.
Sirtuins kanye resveratrol incazelo
Izinga lemibiko: eliqaleni noma elisha
Yini. I-Sirtuins iyimindeni yezinhlayiyana, eziyisishiyagalombili ezinamazinyosi, esebenzisa i-NAD+ ukuphatha ukulungisa i-DNA, ukuguqulwa kwezinto eziphilayo kanye nemisebenzi ye-gene. Ngo-2003 ucwaningo lwathola ukuthi resveratrol, i-compound etholakala ezithelo ezibomvu, yasebenza sirtuin futhi yandisa impilo ye-yeast (Howitz et al., 2003). Ngo-2006 resveratrol wathuthukisa impilo kanye nokuqhubeka kwezinyosi nge high-calorie ukudla (Baur et al., 2006). Ngo-2008 inkampani yemithi GSK wathenga Sirtris, inkampani ethuthukisa sirtuin activators, mayelana $ 720 million (GSK noSirtris, 2008).
Iyini isizathu sokuthi kuphelile. Izindaba azizange zihlale kahle. Resveratrol akazange uqhubekele phambili isikhathi sokuphila kwezinyosi ezijwayelekile nge ukudla okujwayelekile (Pearson et al., 2008), kuhlanganise ne Interventions Ukuhlolwa Program (Miller et al., 2011). I-biochemists yathola ukuthi ukuqapha kwayo okucacile kwe-sirutin SIRT1 kuxhomekeke ekusetshenzisweni kwe-fluorescent tag eyenziwe ngokwezifiso esetshenziswa kukuhlolwa (Kaeberlein et al., 2005; Pacholec et al., 2010). Nomphumela wempilo oyinhloko wesintu esingeziwe ezinhlanzini nezilwane eziphilayo waphela kakhulu lapho izizinda ze-genetic zilawulwa kahle (Burnett et al., 2011).
Into ehlala ithembekile. Izinkomba zibalulekile. Izinkomo ezithuthukisiwe ukwenza ngaphezulu kwesiruthine esisodwa, SIRT6, zahlala isikhathi eside: amadoda kuphela kucwaningo lokuqala (Kanfi et al., 2012), futhi ekugcineni ucwaningo 27% ubude bempilo emiphakathini yabantu abadala naphezu kwe-15% kubantu besifazane, ngokuphazamiseka okuncane (Roichman et al., 2021). Lokhu kuyi-genetic, hhayi iphilisi. Akukho sirtuin-activating isithako siboniswe ukuba kunciphisa ubudala abantu.
I-telomeres ne-telomerase
Izinga lemibiko: eliqaleni noma elisha
Yini. I-telomeres yimikhawulo ephindaphindwayo ye-DNA evala amaphaphu e-chromosomes ethu, njengezikhombisi zepulasitiki eziphezulu zezikebhe. Zinciphisa kancane uma amaseli ahlukaniswa; lapho zincane kakhulu, iseli liyeka ukuhlukaniswa noma lifa. I-enzyme ebizwa nge telomerase ingazivuselela. U-Elizabeth Blackburn, uCarol Greider noJack Szostak bahlukanise i-2009 Nobel Prize in Physiology or Medicine ngokuthola ukuthi lokhu kusebenza kanjani (Nobel Prize, 2009).

Kuzilwane. Ngo-2012 iqembu eSpanish National Cancer Research Centre lanikeza izimvu ezikhulu ukwelashwa kwe-gene okuguqula i-telomerase emuva. Median lifespan rose by 24 percent in mice treated at one year old and 13 percent in mice treated at two years, with no increase in cancer (Bernardes de Jesus et al., 2012). Kuhlala kuyimiphumela ebalulekile kodwa eningi ayiphindelwe.
Inkinga yesifo sikashukela. I-Cancer cells idinga ukuhlukaniswa ngaphandle komkhawulo, futhi ingxenye enkulu yazo yenza lokhu ngokushintsha i-telomerase: kucwaningo oluphawulekayo, amasampula angama-90 we-101 anesilonda ayenamsebenzi we-telomerase, futhi akukho okunye kwama-50 e-normal tissues ayenawo (UKim nokunye, 1994). Abantu abazobe bethola ama-telomeres angaphezu kwamandla abo banesingozi esiphansi sokugula kwenhliziyo kodwa singozi ephakeme yezinkinga eziningi zesifo sikashukela, kufaka phakathi i-glioma, i-adenocarcinoma yephunga kanye ne-melanoma (Haycock et al., 2017). I-telomeres encane ayiyona nje “ebi” futhi i-long ones “engcono”.
Kubantu. Ezinye izifo ezincane ezitholakale, ezinjenge-dyskeratosis congenita, zibangela i-telomerase engekho kahle futhi zenza ukuthi ugogo lwethambo lusebenzenga kahle, ukuvuvukala kwezinso nokufa kwasekuqaleni (Armanios noBlackburn, 2012). Kulesi sifo, i-hormon danazol yandisa amatelomeres kubantu abangu-11 kubantu abangu-12 abakwazi ukucwaswa (Townsley et al., 2016). Lokhu kuyimithi yokwelashwa kwezifo ezincane, hhayi ukukhuluphala. Be skeptic nganoma yisiphi isikhalazo sokuthi imikhiqizo noma iklinikhi “ilungise amatelomeres akho” ukuze ukhule: ngo-2015 umphathi wenkampani eyodwa uthe wathola ukwelashwa kwe-telomerase gene okungaqinisekisiwe ezweni langaphandle, kodwa izikhalazo azikaqinisekiswa ngokuzimela kucwaningo oluhlobene nokuhlolwa (MIT Technology Review, 2015).
Ukuhlela kabusha okuncane ngezinto ze-Yamanaka
Izinga lemibiko: linamandla emidlalweni yezilwane, isivivinyo sokuqala somntu siqhubeka
Iyini le nto. Ngo-2006 uShinya Yamanaka wabonisa ukuthi ukushintshana kwe-jenes ezine kuphela, okwamanje kubizwa ngokuthi ama-Yamanaka factors (OCT4, SOX2, KLF4 ne c-MYC, noma OSKM), kuguqula iseli elikhulayo lesikhumba libe yiseli elisha elifana nebele elikwazi ukuba yinoma yiluphi uhlobo lweseli (Takahashi noYamanaka, 2006). Wabelana nge-2012 Nobel Prize ngalo (Nobel Prize, 2012). Ngendlela, ubudala beseli luhlanzwa: ama-chemical marks ku-DNA ayo abuyela kumamodeli obudala. Inhloso ye ukuphinda udwebe kabusha okuncane ukushintsha izizathu ngokuqondile, isikhathi eside ngokwanele ukubuyisela uphawu lwesikhathi kodwa hhayi isikhathi eside ngokwanele ukuthi iseli likhohlwe ukuthi yini.

Kuzilwane. Ngo-2016, izinja ezineminyaka eminingi zathola i-OSKM ngezikhathi ezithile, ngosuku olulodwa futhi usuku oluhlanu olungasebenzi. Izitho zabo zabonisa izimpawu ezincane zokukhuluphala futhi baphila isikhathi eside (Ocampo et al., 2016). Ngo-2020, izizathu ezintathu (OSK, ushiya ngaphandle i-c-MYC ehlobene ne-cancer) zathunyelwa emakhaleni wezinhlanzi ezinesilonda esifana ne-glaucoma kanye nezilwane ezidala, futhi zibuyisele ukubukeka kwabo ngokubuyisela amaphawu ku-DNA yeseli labo le-nerve (Lu et al., 2020). Uhlelo olude lokuhlela kabusha okuncane kwezinkomo ezijwayelekile ezineminyaka eminingi ubudala lwashintsha izibonakalisi eziningi ze-molecule ziye endaweni encane (Browder et al., 2022), futhi kucwaningo oluncane, imithi ye-OSK gene enikezwa izinkomo zamadoda akhulu kakhulu yaphinda iphinde inani labo elisele lempilo (Macip et al., 2024).

Ingozi. Ukuya eduze kakhulu kuyingozi. Uma lezi zinto zishintshwa ngokuqhubekayo ezinyangeni eziphilayo, amaseli alahlekelwa ukubonakala kwawo futhi akhiqiza izilonda ezibizwa nge-teratomas (Abad et al., 2013); esinye isifundo, OSKM oqhubekayo wabangela isifo sofuba kanye nezinkinga ze-intestine nokufa ngaphakathi kweviki (Parras et al., 2023). Ukuphatha isilinganiso, isikhathi kanye nokuthi iziphi iziseli ezithola ama-gene yinkinga enkulu.
The companies and the first trial. Partial reprogramming has attracted some of the largest investments in biotechnology. Altos Labs yaqala ngoJanuwari 2022 nge-$3 billion (Altos Labs, 2022). Retro Biosciences, exhaswe ngama-$180 amazigidi nguSam Altman (MIT Technology Review, 2023), isebenza ngokuhlela kabusha futhi ithi utshwala lwayo lokuqala, iphilisi elibhekisa ekusebenziseni kabusha kweselula, lafika kusigaba se-1 sokuzama 2025 (Retro Biosciences, 2026). NewLimit iqoqe ama-$435 ayizigidi ezingu-2026 futhi ithi ihlela ukubhekana kokuqala nomuntu ngemithi yokudla (NewLimit, 2026). Ukwelashwa kokuqala kokuhlela kabusha ukufinyelela abantu yi ER-100 kusuka ku Life Biosciences, ukwelashwa kwe-OSK gene okufakwe emehlo ngenxa yezifo ezimbili ze-optic nerve, i-glaucoma ne-non-arteritic anterior ischaemic optic neuropathy (NAION). I-US Food and Drug Administration iqinisekisile ukuphenywa ngoJanuwari 2026 (Life Biosciences, 2026), futhi isiguli sokuqala saphathwa ngoJuni 2026 esigabeni se- 1 ucwaningo lwempilo lwaba 18 abantu (ClinicalTrials.gov NCT07290244; Life Biosciences, 2026). Iziphetho zizothatha iminyaka. Izimemezelo zenkampani azikho izimpawu ezibuyekeziwe, futhi sizovuselela leli khasi njengoba izimpendulo zishicilelwa.
Okunye okubi kakhulu
Amaphilisi athuthukisa impilo yegundane
Izinga lemibiko: linamandla emithonjeni yenyama
Ngo-2004, iphrojekthi yokuhlola ukungena yenziwe ngezinto ezingu-54 ezingaphezu kuka-30,000 zezinhlanzi (Jiang et al., 2025). Ukwakhiwa kwayo kunzima: ukuhlolwa okufanayo kwenziwa ezibhedlela ezintathu, ngezinhlanzi ezahlukahlukene ngokwezenhlalo, ngakho-ke imiphumela kufanele ihlale kuyo yonke. Ngaphandle kwe-rapamycin, ama-compounds amaningi adlule: imithi yesifo sikashukela acarbose yangeza i-22% yokuphila okuphakathi kwamadoda kodwa kuphela i-5% kubantu besifazane (Harrison et al., 2014); 17-alpha-estradiol, uhlobo oluncane lwe-estrogen, lafaka i-19% kubantu besifazane futhi akukho kubantu besifazane (Strong et al., 2016); kanye nemithi yesifo sikashukela canagliflozin yafaka i-14% kubantu besifazane kuphela (Miller et al., 2020). I-Rapamycin ehlobene ne-acarbose yanikeza izinzuzo ezinkulu kuze kube manje: amaphesenti angama-34 kubantu besifazane namakhulu ayisishiyagalombili (28) amadoda (Strong et al., 2022). Kungani amadoda athola inzuzo njalo njalo kuyimibuzo ebalulekile. Akunalutho lwalezi zidakamizwa ezihlolwe ukuthi zingaba nomthelela ekukhululeni kobudala kubantu.

I-Metformin ne-TAME trial
Izinga lemibiko: eliqaleni noma elisha
I-Metformin iyimithi ebiza kakhulu yokulwa nesifo sikashukela esetshenziswa iminyaka engamashumi ayisishiyagalombili. Ucwaningo lwe-2014 lwezibalo zezempilo zase-UK lwathola ukuthi abantu abanesifo sikashukela abathatha i-metformin baphila isikhathi eside kunalabo abangaba nesifo sikashukela (Bannister et al., 2014), okwenze yabe yisinqumo esiphambili semithi yokuvimbela ukukhuluphala. I- I-TAME Ucwaningo olusha (Ukubhekana Nokukhuluphala Nge-Metformin) lwahlelwe ukuvavanya ukuthi imisa kanjani ukugula kwenhliziyo, isifo sofuba, i-dementia kanye nokufa ndawonye kubantu abadala abakhulu, futhi likhuthaze abaqondisi ukuba baphathe ukukhuluphala njengento enjalo odokotela bangayikhomba (U-Barzilai nokunye, 2016). NgoSepthemba 2026 asikwazi ukuthola imiphumela eshicilelwe. Ngoba isinqumo sisondelene: ucwaningo lwe-Danish olubandakanya ama-twins lwathola ukuthi akukho inzuzo yokuphila efinyeleleka kubantu abasebenzisa i-metformin (Keys et al., 2022); i-metformin kuphela ayizange ithuthukise kakhulu impilo yegundane kwi-Interventions Testing Program (Strong et al., 2016); futhi ezinyangeni ezimbili zokuhlolwa kweziguli ezikhulu zibone ukuthi kunzima ukuqeqeshwa kokuzivocavoca (Konopka et al., 2019; Walton et al., 2019).
Imithi ye-GLP-1
Izinga lemibiko: lithembisa ukucwaswa kwabantu
Izidakamizwa ezifana ne-semaglutide zifana no-GLP-1, i-hormone ye-intestine, futhi zathuthukiswa ukwelashwa kwesifo sikashukela nokukhuluphala. Ku-SELECT trial of 17,604 abantu abanesisindo esiningi kanye nesifo senhliziyo, i-semaglutide yanciphisa izimo zenhliziyo, izidumbu nezifo zenhliziyo ngo-20% (Lincoff et al., 2023). Ucwaningo lwabakhulu be-US abanesifo sikashukela luxhumene namaphilisi we-GLP-1 nokunciphisa umngcipheko wezimo eziningi, kufaka phakathi i-dementia, ukubhema nokutheleleka, kanye nomngcipheko ophezulu wokunye, njengokungasebenzi kahle kwe-digestive ne-pancreasitis (Xie, Choi and Al-Aly, 2025), kodwa ucwaningo olunjalo lwezifundo zokuhlola alukwazi ukuveza isizathu. Nakuba kulezi zifundo ezimbili ezinkulu eziqaleni zesifo se-Alzheimer, i-semaglutide ethathwa ngomlomo ayizange ikhawulele ukuncipha (Cummings et al., 2026). Lezi ziyimithi enamandla yokwelashwa kwezifo ezithile; uma zihamba kancane ukukhuluphala, asikho isiqiniseko sokuthi zingasebenza kanjani.
Ukunciphisa i-calorie
Izinga lemibiko: lithembisa ukucwaswa kwabantu
Ukudla okuncane ngaphandle kokulahlekelwa ukudla kwenza impilo ibe banzi emidlalweni eminingi, futhi kwakuyisinqumo sokuqala “sokulwa nokukhuluphala” esitholakale. Ku-monkeys, izifundo ezimbili ezinkulu zesikhathi eside ekuqaleni zabonakala zingavumelana, kodwa ucwaningo oluhlangene lwa concluded ukuthi ukuvimbela i-calorie kwenza ukunakekelwa kwempilo nokuqhubeka kokuphila lapho imininingwane ye-diet neminyaka ithathwa engqondweni (Mattison et al., 2017). Ku-CALERIE 2 trial, 218 onesifo sikashukela, abangama-obesive abadala bacela ukuba baphuze amaphesenti angama-25 aphansi iminyaka emibini futhi baphatha amaphesenti angama-12. Ukushisa kwegazi, i-cholesterol kanye ne-insulin sensitivity yabo kwathuthukiswa (Kraus et al., 2019), futhi ukuhlolwa kokuhamba kobudala bemvelo, iDunedinPACE, kwancipha ngo-2 kuya ku-3%, nakuba ezinye izikhashana ezimbili azishintshi (Waziry et al., 2023). Ukunciphisa inani le-calorie kungalimaza amathambo namathambo, futhi akuphephile kubantu abanezinkinga zokudla noma ababhekene nengozi yokuzibulala, noma abantu abadala abancane.
Ushintsho lwegazi neplasma
Izinga lemibiko: eliqaleni noma elisha
Uma ukujikeleza kwegundane elidala nelingumncane kuxhunywe, ezinye zezitho zegundane elisha, ezinjengemisipha ne-liver, zilungisa ngokwazo kahle (Conboy et al., 2005). I-protini eyodwa yegazi, i-GDF11, yaphawulwa njengengxenye yokuvuselela, kodwa umsebenzi olandelayo awukwazi ukubuyisela imiphumela (Egerman et al., 2015). Abanye abacwaningi manje bacabanga ukuthi ukulahleka kwezinkomba ezibi emlonyeni omusha kubaluleke kakhulu kunalokho ukufaka amancane: ezinhlanzi ezindala, ukushintsha kuphela inhlamvu ye-plasma nge-salt ne-albumin solution kunciphisa isisindo, i-liver kanye nohlelo lwengqondo (Mehdipour et al., 2020). I-Placebo ilawulwa ngokuzivocavoca okuncane, ushintsho lwe-plasma yokwelashwa (ukuguqula i-plasma nge-albumin) washintsha amahora ambalwa e-epigenetic ukuya esikhathini esincane (Fuentealba et al., 2025), futhi empilweni yokuhlolwa kwesifo se-Alzheimer’s kwancipha ukwehla kwezinsizakusebenza zosuku zonke kubantu abanesifo esiphakathi (Boada et al., 2020). Ngo-2019 i-US Food and Drug Administration yathi iziguli ukuthi ukukhishwa kweplasma kusuka kubahlinzeki abancane “akukho inzuzo eqinisekisiwe yeklinikhi” futhi kunezinzuzo ezingokoqobo (I-FDA, ngo-2019).
Amahora e-epigenetic: ukukala ubudala bemvelo
Ithuluzi lokulinganisa, hhayi ukwelashwa
Ukuhlola ukuthi ngabe yini ehamba kancane ukukhuluphala, abacwaningi badinga indlela yokulinganisa ngaphandle kokulinde iminyaka eminingana. Izikhali ze-epigenetic zifunda amaphawu wekhemikhali (i-methylation) emazweni amakhulu ku-DNA futhi zilinganisela ubudala kusuka kwimodeli. Okuqala, nguSteve Horvath, wasebenza emithonjeni eminingi yesikhumba (Horvath, 2013; Hannum et al., 2013). Ihora elilandelayo laqeqeshwa ukubikezela impilo ngaphezu kobudala bekhalenda: PhenoAge (Levine et al., 2018), GrimAge, enamandla okubikezela isikhathi sokufa (Lu et al., 2019), kanye ne DunedinPACE, elinganisela ukuthi umuntu ukhula kanjani ngokushesha manje, njenge-speedometer (Belsky et al., 2022). Abantu abazobe behamba phambili eminyakeni yabo bafa ngokushesha (Chen et al., 2016).
Okunye okungeke bakwazi ukusitshela: ukuthi ngabe ukuguqula ihora emuva kwenza umuntu abe nempilo engcono. Ukwelashwa kungashintsha ama-mark ngaphandle kokushintsha i-biology engezansi. Amahora angaba nezwi: isampula elilodwa legazi elilinganiselwe kabili linikeze ukufundwa kuze kube yiminyaka emihlanu, nakuba izibuyekezo ezithuthukisiwe zinciphisa lokhu (Higgins-Chen et al., 2022). Ukuhlolwa kwe-”ubudala bemvelo” kuhlukile futhi akudingeki ukuthi kuqondise izixazululo zezokwelapha.
Okusho ukuthi,
Izinga lemibiko: liqinisekisiwe kubantu
Uma isayensi engezansi ikhula, isivivinyo esinamandla kakhulu seminyaka engcono kakhulu yokuphila sivela emikhubani nemithi ehlolwe kubantu abaningi. Akunalutho lwazo olubuyisela emuva ukukhuluphala, kodwa ngokuzimela zimisa izifo zeminyaka ngonyaka, futhi uninzi lwazo lubiza kancane noma akukho.
Umsebenzi wenyama. Inhlangano Yezempilo Yezwe icebisa imizuzwana engu-150 kuya ku-300 yokuzivocavoca okuncane, noma imizuzwana engu-75 kuya ku-150 yokuzivocavoca okunamandla, ngaso sonke isiviki, nokuziqinisa kwamathambo ngezinsuku ezimbili noma ngaphezulu futhi, kubantu abadala abakhulu, ukuqeqeshwa kokulingana ukuze kuvimbele ukugwama. Umsebenzi ojwayelekile uxhunywe nokunciphisa umngcipheko wesifo senhliziyo, i-stroke, uhlobo lwe-2 lwesifo sikashukela, izifo eziningi zesifuba, ukukhathazeka nokukhubazeka (WHO, 2020). Ukuqeqeshwa kwesisindo sithuthukisa amathambo kuwo wonke abesifazane.

Akukho ukushaya. Abantu abayeka ukushaya ngaphambi kobudala obungu-40 bavimbela ngaphezulu kuka-90% yengozi engaphezulu yokufa ekuqhubekeni (Jha et al., 2013). Ukuyeka nganoma yisiphi isikhathi kusiza.
Isici sokushisa kwegazi kanye ne-cholesterol. Kulesi sifundo se-SPRINT, ukulawulwa okuqinile kokushisa kwegazi kunciphise izimo zenhliziyo nezifo, futhi kunciphise ukulimala okuncane kokucabanga (SPRINT MIND, 2019). Ubuhlungu benhliziyo obuphezulu kungekho zibonakaliso zobukhona, ngakho-ke ukulinganisa kuyindlela ekahle yokwazi.

I-Diet. Kulesi sifundo se-PREDIMED, ukudla kweMedithera okuthosiwe nge-olive oil noma ama-nuts kunciphise izimo ezinkulu ze-cardiovascular ngamaphesenti angama-30 uma kuqhathaniswa ne-fat-reduced diet (Estruch et al., 2018). I-WHO ichaza ukuthi akukho izinga lotshwala oluphephile empilweni; okuncane kungcono.
Ukuhlala uphumule. Abakhulu bakhuthazwa ukuba bahlale bephumula cishe amahora ayisithupha ngesonto (Watson et al., 2015); ukuphumula okuncane noma okungakhululeki isikhathi eside kuhlobene nokugula kwenhliziyo nesifo sokudla, futhi ukuphefumula ngesikhathi sokuphumula kuyinto ejwayelekile futhi ingaxazululwa.
Ukuxhumana kwezenhlalo. Ku-meta-analysis enkulu, abantu abanezingxoxo zomphakathi ezinamandla babe nezinga elingaphezu kuka-50% lokuqhubeka nokuphila ngesikhathi socwaningo (Holt-Lunstad et al., 2010).
Ukuzwa, ukubukeka nokugonywa. Ukulahlekelwa ukukhuluma kuyisihluthulelo esincane esishintshayo sokugula kwengqondo esichazwe yi-Lancet Commission, exhumana nephesenti le-45 lezimo zesifo sikashukela nezizathu ezingu-14 ezishintshayo (Livingston et al., 2024). Kulesi sinqumo sokuthola, ukuphendula kokulalela kusheshise ukwehla kokuqonda ngo-48% eminyakeni emithathu phakathi kwabakhulu abaneminyaka engaphezu kwengu-Lin et al., 2023). Ucwaningo olujwayelekile e-Wales lwathola ukuthi ukwelashwa kwe-shingles kwalandela ukuxilongwa okuncane kuka-20% kwezifo zengqondo eminyakeni eyisikhombisa (Eyting et al., 2025).

Uma izindawo zonke zishintsha. Izinzuzo ezinkulu zavela lapho izinhlangano zishintsha ndawonye. In North Karelia, Finland, a region-wide programme from 1972 cut smoking, cholesterol and blood pressure, and deaths from coronary heart disease among people aged 35 to 64 fell by 82 percent in men and 84 percent in women by 2012 (Jousilahti et al., 2016; Puska et al., 2016). Ngemuva kokuthi iScotland ivumele ukushaya utshwala ezindlini zomphakathi ezivulekile ngo-2006, iziguli ezitholakele ezindaweni zokuhlinzwa ngenxa yezifo zenhliziyo kanye ne-angina engazinzi zancipha ngamaphesenti angama-17 ngonyaka (Pell et al., 2008). I-Finland FINGER trial, izinhlelo zeminyaka emibini zokuzivocavoca umzimba, ukuqeqeshwa kwengqondo kanye nokuhlolwa kwezinhlayiyana kuthuthukise ukuqonda nomlando kubantu ababhekene nengozi yokukhubazeka (Ngandu et al., 2015), futhi eTaketoyo, eJapan, abantu abadala abathatha inxaxheba ezindlini zomphakathi babe ngamaphesenti afanayo okukhula kwezinkinga zengqondo eminyakeni emihlanu (Hikichi et al., 2015).
Ukwelapha okunamandla kakhulu okuphila isikhathi eside okuhlolwe ngaphambili akudingeki ukuthi kube khona: ukugibela, ukuhlala uphumule, ukungaphuzi kanye nokuqhubeka nokuxhumana. Isinkolo esitsha sifuna ukungeza kuzo, hhayi ukuzishintsha.
Ukuphila okunempilo isikhathi eside kungashintsha kanjani inani labantu
Izwe libhekene noshintsho olukhulu empilweni yabantu, olukuningi kakhulu kunalokho okudlule. Ngokusho kwe-United Nations, isilinganiso sokukhula komhlaba wonke manje siyizinkanyezi ezingu-2.25 zokuphila ngayinye yomntwana, isuka ku-3.31 ngo-1990; ngaphezulu kwesigamu sezwe lonke kanye nezifundazwe zinomthelela ophansi kakhulu wokushintshana kwamaphesenti angama-2.1, futhi cishe umuntu ngamunye emibili angaphansi kuka-1.4. Inani labantu emhlabeni, elingaphezu kuka-8.2 billion ngo-2024, lilindeleke ukuthi lifike kuma-10.3 billion phakathi kwekhulu le-2080s futhi likhuphuke kancane libe ngama-10.2 billion ngo-2100. Ezweni le-63 kanye nezifunda, ezibamba iphesenti le-28 lomhlaba wonke, inani labantu lifinyelele esiphethweni. Ngokuphela kwekhulu le-2070, abantu abaneminyaka engu-65 nangaphezulu balindeleke ukuthi badlulele izingane ezingaphansi kweminyaka eyi-18 (UN World Population Prospects 2024). Izizathu zokuwa kwesisindo, nokuthi kungani i Local Solar System Foundation ixhasa ukufundisa kanye nokukhethwa okungokoqobo kwanoma iyiphi intsha, zibekwe kukhasi lethu elibhalwe ngokuthi umphakathi, ukubhema nokusetshenziswa kwezinsiza.
An older population is usually described as a burden: fewer workers supporting more retirees. Ukuhlolwa okujwayelekile, i-old-age dependency ratio, ibala abantu abaneminyaka engu-65 nangaphezulu kwabangu-100 abantu abaneminyaka engu-20 kuya ku-64. Ibalo le-UN libonisa ukuthi ngo-2024 izwe lizoba nezigidi ezingama-18, kanti ngo-2050 lizobe liyizinkulungwane eziyi-29 futhi ngo-2100 lizoba yizigidi ezingama-44; eJapane liyizigidi ezingama-55 (UN World Population Prospects 2024).
Ubudala abuyona inani eliqinile
Lo mphumela ukholelwa ukuthi umuntu oneminyaka engu-65 ngonyaka ka-2100 uzobe encane kakhulu kunalowo oneminyaka engu-65 ngonyaka ka-1950. Abacwaningi bezenhlalakahle uWarren Sanderson noSergei Scherbov bakholelwa ukuthi lokhu kuholela ekukhohliseni. Baphakamise ukulinganisela ubudala ngezinyanga abantu abashiyele ukuba baphile, hhayi izinyanga ababeziphila kuzo, futhi babonisa ukuthi inani labantu linga “khula lincane” ngalolu hlobo lokulinganisela nakuba iminyaka yabo ephakathi ikhuphuka (Sanderson noScherbov, 2005; Sanderson noScherbov, 2010). Uhlobo olulodwa lubeka umkhawulo weminyaka edlule lapho ukuhlala okulindelekile kungaphansi kweminyaka engu-15: kwabesifazane baseFrance, kwakuyi-58 ngo-1900 futhi kunama-75 ngo-2012 (Sanderson noScherbov, 2015).
Igama elibalulekile yi healthy. Ngomhlaba wonke, ukulindeleka kokuphila kwehla kusuka eminyakeni engu-66.8 kuya ku-73.1 phakathi kuka-2000 no-2019, ngenkathi ibanga eliphakathi kokulindeleka kokuphila nokulindeleka kokuphila okunempilo liwukhula kusuka eminyakeni engu-8.5 kuye ku-9.6 (WHO Global Health Observatory; Garmany neTerzic, 2024). Unyaka ongeziwe odlulele ekunakekelweni okungalungile kungeza ubunzima emiphakathini kanye nezinhlelo zokunakekelwa kwempilo. Unyaka ongeziwe wempilo engcono uhlukile: abantu bangaqhubeka besebenza uma befisa, bakhathalele abanye, basebenze ngokuzinikela, bafunde futhi basize. Lokhu kusho ukuthi isayensi kule khasi ibalulekile kubantu, hhayi kuphela kubantu.
I-chart engezansi iyisibonelo, hhayi ukubikezela. Isebenzisa inani lezigidi ezilindelekile ze-UN futhi ibuza umbuzo owodwa: uma abantu bethola iminyaka ephephile neminyaka lapho bavame ukuyeka umsebenzi futhi bedinga usizo oluningi likhuphuka nabo, ngabe kuzoba kanjani ukuthi inguquko yesilinganiso? Uma lo mgca usuka ku 65 kuya ku 70, izwe le 2100 lizobe linezivakashi ezingaphezu kuka-31 ngazo zonke izivakashi ezineminyaka engu-100 esebenza khona endaweni ye 44; ku 75, mayelana no 21, eduze kwezinga lanamuhla. Izinqumo zikhulu: ukuthi iminyaka engaphezulu iphephile, ukuthi umsebenzi kanye nezimali zokukhokha izibopho zomsebenzi ziyashintsha, futhi ukuthi izinzuzo zifinyelela kuwo wonke umuntu, hhayi kuphela labo abacebile.
Ukunakekelwa kwezingane
Abazali bathola izingane ezincane kakhulu ngaphezu kwanoma yikuphi. Ezweni lonke le-OECD, ubudala obuphakathi kwamamama ngesikhathi sokuqala ukuzalwa kwakhula kusuka ku-26.4 ngo-2000 kuya ku-29.6 ngo-2024 (i-OECD Family Database). The ovaries show marked ageing earlier than most other tissues in the body (Garrison, 2026), and declining fertility in the late thirties and forties limits how many children people who start later can have. Ucwaningo lokukhula kobudala ngoku ingxenye ye-geroscience: isibonelo, ukuhlolwa kwe-VIBRANT eColumbia University kuhlolwe ukuthi ngabe i-rapamycin enedosi eliphansi ingasheshisa ukulahleka kwezinkukhu ezincane kubantu besifazane abaneminyaka engu-35 kuya ku-45 (ClinicalTrials.gov NCT05836025); imiphumela yayo ayikho okwamanje. Uma ukukhuluphala kokuzala kunganciphiswa ngokuphephile, abantu abafuna izingane bangaba nezingane ngemuva kwalokho, ngaphandle kokuqhuma kwefasitela lokuvala.
Kungani abaningi abacwaningi bezenhlalakahle balindele ukuncipha
Kubalulekile ukuba nobuhlakani mayelana nemibono ephikisanayo. Abacwaningi be-Global Burden of Disease balindele ukuthi 155 kwezizwe ezingu-204 nezifundazwe zibe nezinga lokuzala elingaphansi kokushintshana ngo-2050 kanye no-198 ngo-2100; ezizweni ezingu-47 lapho izinga lokuzala liphinde lakhula khona, yilezi ezintathu kuphela ezibuye zabuyela ngaphansi kokuguqulwa (GBD 2021 Fertility and Forecasting Collaborators, 2024). I-UN icabanga ukuthi amazwe anezinga eliphansi kakhulu lokuzala alabo abahlali babo bafinyelele ezingeni eliphezulu, akulindelekile ukuthi babuye baphinde bashintshwe eminyakeni engu-30 (UN World Population Prospects 2024). Abaningi i-low-fertility trap, lapho izizukulwane ezincane, ubukhulu bemindeni engcono kakhulu kanye nobunzima bomhlaba wonkeLutz, Skirbekk noTesta, 2006), kanye economicists Dean Spears noMichael Geruso bathi ngaphandle koshintsho esigabeni, inani labantu emhlabeni kungancipha isikhathi eside ngemuva kwayo iphoyinti (Spears noGeruso, 2025). Ukuphila okude kuphela akuxazululi lokhu: kukhawulela ukuncipha, kodwa ngesikhathi eside inani lenzalo ezincane kakhulu lihlala lincipha.
Isibonelo: ukuncipha kuyinkinga yesikhathi eside
I- Local Solar System Imibono ye-Foundation ukuthi ukuncipha kwezigidi iphutha elingakapheli, ukuguquka ukuze kushintshwe kunenkinga ehlala njalo. Sibonisa lokhu njengengxoxo, ngezinto zethu kanye nezimpawu ezikhombisa ukuthi kuyiqiniso noma ayilungile.
Isiqiniseko.
- Ukuphila okunempilo kufakazela ukuthi izibeletho ezincane zidingeka ukuze kube khona inani elihlala liqinile. Kubantu abakhula noma bekhuphuka, ubukhulu babo bulingana nenani lezizalwa ngonyaka olu multiplied ngesikhathi sokuphila esilindelekile ngesikhathi sokuzalwa, i-identity eyinhloko yedemographics (Preston, Heuveline and Guillot, 2001). Uma ukulindeleka kokuphila kukhule kusuka eminyakeni eyi-73 kuya kweyi-90, inani elifanayo lenzalo lingagcinwa ngomnyaka ngamunye.
- Impilo, hhayi ubudala, ikhetha ukuthi ngubani odinga ukuxhaswa. Uma i-geroscience imisa izifo zeminyaka ngisho ngeminyaka embalwa, inkomba yokungathembeki okusebenzayo ingahlala eduze kwezinsuku ezizayo nakuba inani labantu likhula likhulu, njengoba kuboniswe kwi-chart ngasentla.
- Ifasitela elide lokuzala lingavumela abantu ukuthi babe nezingane abafunayo. Uma ukukhuluphala kokuzalwa kunganciphiswa ngokuphephile, ukunakekela izingane kuqala ngeke kubhekise ekubeni nezingane ezincane.
- Izinjabulo ziphinde zabuya phakathi kwezizwe ezithuthukisiwe kakhulu, ezinye izifundo zathola ukuthi ukuqhubeka kokukhula kuhlobene nokunyuka kwezinjabulo (Myrskylä, Kohler noBillari, 2009), ikakhulukazi lapho umsebenzi nempilo yomndeni ilula ukuxhuma (Luci-Greulich noThévenon, 2014), kepha lesi siphetho siphikisana (Harttgen noVollmer, 2014).
- Ukwehla okuncane kunikeza isikhathi sokushintsha. I-UN ilindele ukunyuka okuphansi nokuncipha okuncane kulekhulu, hhayi ukuwa, okusho ukuthi kuzothatha iminyaka eminingi ucwaningo, umsebenzi kanye nenqubomgomo yomndeni ukuze kushintshwe.
Iyini eyenza ukuhlolwa. I-hypothesis izothola insizakalo uma: ukulindeleka kokuphila okunempilo kunyuka ngokushesha kunesikhathi sokuphila, kuvula ibanga; isivivinyo sibonisa ukuthi ukungena ngaphakathi kuvimbela izifo eziningi zeminyaka ngasikhathi sinye, njengoba i-TAME yakhiwa ukwenza; ukuzalwa eminyakeni edlulele ukukhula kakhulu ukuze ubukhulu bemindeni obuqediwe bugweme ukuwa; futhi ukubikezela ubungozi bobudala obukhulu obulinganiselwe ngokunakekelwa kwempilo, hhayi ngobudala obuqinile, buhlala buqinile. Kuzobuthakathaka uma ibanga leminyaka ephephile liqhubeka nokukhula, uma izifundo zokuqala zabantu ze-rapamycin, senolytics kanye nokuhlela kabusha zihlulekile, futhi uma ukukhulelwa kuqhubeka kukhuphuka ngisho nalapho abazali bephila impilo ende, ephephile, usizo oluhle nokukhetha okungokoqobo. Sizolandela isivivinyo futhi sihlaziye le khasi uma kufika.
Izwe elinabantu abancane, abaphila isikhathi eside lingaba neplanethi ekhanyayo, ngakho-ke lesi simbuzo sihlobene nomsebenzi we Local Solar System Foundation ku ukulingana phakathi kwabantu namathuluzi.
Khumbula: izithako, amaklinikhi kanye nokuzama-ukwenza
Izinhlangano ezisebenza kulolu msebenzi
Lezi zinhlangano ezingathola inzuzo zishicilela lokho ezikwenzayo futhi zibike iziphetho ezilinganiselwayo. Uma ufuna ukuxhasa ukukhula okunempilo, bheka umsebenzi wabo bese ucabanga ngokunikeza ngokuqondile, ngewebhusayithi yabo. I Local Solar System Foundation ayisebenzisi noma iyiphi yazo futhi ayitholanga lutho kuzo. Phambi kokuba ukhokhe, funda izibalo zeminyaka kanye nezimali zohlelo ngalunye.
- HelpAge International (i-United Kingdom, inhlangano yobuciko ebhalisiwe 288180). Isebenza namaqembu ahlanganyela ezindaweni eziningi ukuze abantu abadala bakwazi ukungena ekuhlolweni kwempilo, ekuhlolweni komphakathi kanye nokuvikelwa kwezinkokhelo, futhi ikhuluma ngelungelo labo.
- Age UK (i-United Kingdom, inhlangano yobuciko ebhalisiwe 1128267). Inikeza usizo olusebenzayo kubantu abadala ababhekana nobuhlwempu, ukuhlukaniswa nokugxekwa, kanye nocwaningo nezinhlelo zokuthuthukisa imithetho.
- Inhlangano Yenhliziyo yaseBrithani (i-United Kingdom, inhlangano yobuciko ebhalisiwe 225971). Uchwepheshe ophezulu wezokwelapha e-UK.
- American Heart Association (i-United States, inhlangano engathola inzuzo ngaphandle kwezimali). Ixhasa ucwaningo lwesifo senhliziyo nesifo somoya futhi iqhuba amaphrojekthi amphakathi okulwa nokutheleleka.
- Alzheimer’s Society (i-United Kingdom, inhlangano yobuciko ebhalisiwe 296645) kanye ne Alzheimer’s Association (i-United States, engatholakali ngezimali). Ucwaningo oluhlobene nokwelashwa nokuzivikela kulesi sifo luyaqhubeka.
Ungasiza kanjani
- Qala ngento eqinisekisiwe. Yihamba kaningi namhlanje, ngeza amandla nokuzivocavoca ukulinganisa, futhi ubuze umhlinzeki wezokunakekelwa kwempilo ukuthi abheke isisindo sakho segazi.
- Ukuhlola ukulalela kwakho nokubheka kwakho, futhi ukhuthaze abazali nabangani bakho ukuba benze njalo.
- Qhathanisa. Nxusa umuntu ongakhuluma naye isikhathi eside; memela umngane ohlala ehlukile ukuba akhulume nawe.
- Funa izifundo, hhayi izikhangiso. Izibalo zivela ezifundweni ezibhalisiwe, ezishicilelwe emithonjeni ebuyekezwa ngabanye.
- Be skeptical of miracle claims, and share this page when you see one.
- Sisiza ukugcina le khasi lilungile. Abacwaningi, abadokotela kanye nabaguquleli bangasebenza ngokuzinikela ku ibhodi lokuhlinzekwa.
Izinsizakusebenza
- U-Kennedy nokunye (2014), Geroscience: ukuxhuma ubudala nokugula okuqhubekayo, Cell 159
- I-Lopez-Otín et al. (2013), Izimpawu zokukhuluphala, Cell 153
- I-Lopez-Otín et al. (2023), Izimpawu zokukhuluphala: i-universe ekhulayo, Cell 186
- I-Goldman et al. (2013), Impilo ebalulekile kanye nemali ebuyiselwa kusuka ekukhululeni okuphelile kungaba yisisekelo esitshalwe kabusha socwaningo lwezokwelapha, Amaqiniso okunakekelwa kwempilo 32
- Scott, Ellison noSinclair (2021), Inani lezomnotho lokugxila ekukhululeni, Ubuciko Bokukhululwa 1
- I-US National Center for Health Statistics (2026), NHIS Adult Summary Health Statistics, 2025, kanye ne NHIS 2025 sample adult file
- I-US National Cancer Institute, SEER*Explorer, ukutheleleka kwesifo sikashukela ngobudala, 2019 kuya ku-2023
- I-Manly et al. (2022), Ukubikezela ukusakazeka kwe-dementia kanye nokukhubazeka okuncane kokuqonda e-US, JAMA Neurology 79
- Garmany noTerzic (2024), Izingcindezi zempilo-ukuphila kwezwe lonke phakathi kwezifundazwe ezingu-183 eziyilungu le-World Health Organization, JAMA Network Open 7
- I-US National Institute on Aging, Izinhlelo Zokuhlonza Ukuhlolwa
- Vézina, Kudelski noSehgal (1975), Rapamycin (AY-22,989), i-antibiotic entsha evimbela izifo zegciwane, Journal of Antibiotics 28
- UHarrison nokunye (2009), I-Rapamycin edliwa ekupheleni kokuphila ithuthukisa impilo yezinyosi ezingenazo izitho zofuzo, Nature 460
- U-Miller nokunye (2011), Rapamycin, kodwa hhayi resveratrol noma simvastatin, ithuthukisa impilo yezinhlanzi ezingenalutho ze-genetic, Izincwadi zeGerontology A 66
- U-Miller nokunye (2014), Ukukhula kwempilo ehlobene ne-rapamycin kugundane kwenziwa ngokuya ngedosi nohlobo locansi, Aging Cell 13
- Mannick et al. (2014), ukunciphisa i-mTOR kuthuthukisa ukusebenza kwe-immune kubantu abadala, Isayensi Yokudluliswa Kwezokwelapha 6
- Mannick et al. (2018), I-TORC1 inhibition ithuthukisa umsebenzi we-immune futhi ikunciphisa izifo ezinesifo sikashukela, Ucwaningo lwezokwelapha 10
- Mannick et al. (2021), Ukubheka i-biology yokukhuluphala nge-mTOR inhibitors ukuthuthukisa ukusebenza kwe-immune kubantu abadala abakhulu: isikhashana 2b nesigaba 3 izifundo ezi randomized, Lancet Healthy Longevity 2
- I-Moel et al. (2025), Imiphumela ye-rapamycin ekuvikeleni nokunakekelwa kwempilo ngemuva konyaka owodwa: Izibalo zePEARL trial, Aging 17
- ULee, uKuerec noMaier (2024), Ukubheka ukukhuluphala nge-rapamycin nemikhiqizo yayo kubantu: ukubuyekezwa okuqhubekayo, Lancet Healthy Longevity 5
- U-Lamming nokunye (2012), Ukulwa ne-insulin eyenziwe yi-Rapamycin kulawulwa yizifo ze-mTORC2 futhi akuxhunyiwe ekusebenzeni kahle, Science 335
- I-US National Library of Medicine, DailyMed: sirolimus prescribing information
- I-Copé et al. (2008), I-Senescence-associated secretory phenotypes ibonisa imisebenzi yeseli-engenayo-i-oncogenic RAS ne-p53 tumor suppressor, PLOS Biology 6
- U-Baker nokunye (2011), Ukwehlisa amaseli asemncane we-p16Ink4a-positive kunciphisa izifo ezihambisana nobudala, Nature 479
- U-Baker nokunye (2016), Izitho ze-p16Ink4a ezikhona ngokuvamile zinciphisa isikhathi sokuphila, Nature 530
- I-Zhu et al. (2015), I-Achilles’ heel yeselula ezincane: kusuka ku-transcriptome kuya kumaphilisi asenolytic, Aging Cell 14
- U-Xu nokunye (2018), I-Senolytics ithuthukisa umsebenzi wengqondo futhi ikhuphule isikhathi sokuphila esigabeni esidala, Ukudla kwemvelo 24
- U-Yousefzadeh nokunye (2018), I-Fisetin iyisenotherapeutic ethuthukisa impilo nempilo, EBioMedicine 36
- Umthetho kanye nokunye (2019), I-Senolytics esifo sofuba esingenalutho: izimpendulo ezivela kumuntu wokuqala, ovulekile, ucwaningo olusha, EBioMedicine 40
- I-Hickson et al. (2019), I-Senolytics ikhuphula amaseli aphilayo emuntu, EBioMedicine 47
- I-Farr et al. (2024), Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial, Imithi Yobuciko 30
- U-Gonzales nokunye (2023), Imithi ye-senolytic esifo se-Alzheimer esincane: isikhashana 1 sokuhlolwa kokusebenza, Nature Medicine 29
- I-Unit Biotechnology (2025), imiphumela yesigaba se-ASPIRE 2b kanye ne-isitifiketi sokukhishwa, i-US Securities and Exchange Commission filings
- I-Mills et al. (2016), Ukusetshenziswa okude kwe-nicotinamide mononucleotide kunciphisa ukuncipha kobudala obuhambisana nobuchopho ezinyoni, *Cell Metabolism * 24
- I-Zhang et al. (2016), NAD + ukugcwalisa kuthuthukisa mitochondrial kanye neseli le-stem umsebenzi futhi kunciphisa isikhathi sokuphila kwezinhlanzi, * Science * 352
- UHarrison nokunye (2021), 17-a-estradiol ekupheleni kokuphila kuthuthukisa impilo yokuphila ekukhuleni kwe UM-HET3 amazinyo omntwana; i-nicotinamide riboside nezinye izidakamizwa ezintathu azithintanga impilo yempilo noma yimuphi umndeni, *Iseli Elikhulayo * 20
- I-Martens et al. (2018), I-Chronic nicotinamide riboside supplementation itholwe kahle futhi ikhuphula i-NAD + kubantu abadala abaphakathi neminyaka kanye nabesifazane abakhulu, * Izindaba Zobuciko * 9
- U-Yoshino nokunye (2021), I-Nicotinamide mononucleotide ithuthukisa ukusabela kwe-insulin yamathambo kubantu besifazane abanesifo sikashukela, Ucwaningo 372
- I-Brakedal et al. (2022), I-NADPARK study: isigaba esihamba phambili sokuhlolwa kwe-nicotinamide riboside supplementation kusifo seParkinson’s, Cell Metabolism 34
- I-Zhang et al. (2025), Impumelelo yokudla okune-nicotinamide mononucleotide ephusheni nge-glucose ne-lipid metabolism kubantu abadala: ukubuyekezwa okuzenzakalelayo, * Izibuyekezo ezibalulekile zeSayensi Yezithelo Nezokudla * 65
- I-Prokopidis et al. (2025), Imiphumela ye-nicotinamide mononucleotide ne-ribose ku-skeletal muscle mass nemisebenzi, Journal of Cachexia, Sarcopenia and Muscle 16
- I-US Food and Drug Administration (2025), ubufakazi bokuthi abantu bafuna ukuxoxisana nge-NMN, i-docket FDA-2023-P-0872
- I-Howitz et al. (2003), Izisebenzisi ze-molecule ezincane ze-sirutin zithuthukisa isikhathi sokuphila se-Saccharomyces cerevisiae, Nature 425
- I-Baur et al. (2006), I-Resveratrol ithuthukisa impilo kanye nokuqhubeka kokuphila kwezinhlanzi ezidla ukudla okune-calorie ephezulu, Nature 444
- I-Pearson et al. (2008), Resveratrol imisa ukuncipha okuphathelene nobudala futhi ifana nezici zokushicilelwa kwezidakamizwa zokudla ngaphandle kokuthuthukisa impilo, *Cell Metabolism * 8
- I-Kaeberlein et al. (2005), Ukusebenza okukhethekile kwe-substrate kwezinsalela nge-resveratrol, *Incwadi ye-Biological Chemistry * 280
- I-Pacholec et al. (2010), SRT1720, SRT2183, SRT1460, ne-resveratrol azikho izisebenzisi eziqondile ze-SIRT1, Incwadi ye-Biological Chemistry 285
- I-Burnett et al. (2011), Akukho miphumela ye-Sir2 overexpression kusikhathi sokuphila kwe-C. elegans ne-Drosophila, Nature 477
- I-GlaxoSmithKline neSirtris Pharmaceuticals (2008), isinqumo sokunikeza isiphakamiso, iKomidi lezezimali kanye nokuguqulwa laseMelika
- I-Kanfi et al. (2012), I-sirutin SIRT6 ilawula isikhathi sokuphila kwezinkomo zamadoda, Nature 483
- Roichman et al. (2021), Ukubuyiswa kwe-homeostasis ye-engine nge-SIRT6 kunciphisa isikhathi sokuphila, Nature Communications 12
- I-Nobel Prize kuPhysiology noma eMedicine 2009 and 2012
- U-Bernardes de Jesus et al. (2012), I-Telomerase gene therapy ezinganeni nezilwane ezincane zivimbela ukukhuluphala futhi zithuthukise impilo ende ngaphandle kokuthuthukiswa kwesifo sikashukela, EMBO Molecular Medicine 4
- UKim nokunye (1994), I-association ekhethekile yemisebenzi yomuntu we-telomerase neselula engapheli nocansi, Science 266
- I-Telomeres Mendelian Randomization Collaboration, Haycock et al. (2017), Isizinda phakathi kwe-telomere length nengozi yesifo sikashukela kanye nezifo ezingaba khona, JAMA Oncology 3
- Armanios noBlackburn (2012), The telomere syndromes, Nature Reviews Genetics 13
- U-Townsley nokunye (2016), Danazol treatment for telomere diseases, NEJM 374
- Takahashi noYamanaka (2006), Isiqiniseko se-pluripotent stem cells kusuka ku-embrionic mouse ne-adult fibroblast cultures ngokusho kwezinkomba ezichazwe, Cell 126
- I-Ocampo et al. (2016), In vivo amelioration of age-associated hallmarks by partial reprogramming, Cell 167
- I-Lu et al. (2020), Ukuhlela kabusha ukubuyisela ulwazi lwe-epigenetic oluncane nokubuyisa umbono, Nature 588
- I-Browder et al. (2022), I-in vivo encane yokuhlela kabusha ishintsha ushintsho lwe-molecule oluhlobene nobudala ngesikhathi sokukhula kwengqondo kwezinhlanzi, Nature Aging 2
- I-Macip et al. (2024), I-gene therapy-mediated partial reprogramming ethuthukisa impilo futhi ibuyisela emuva izinguquko eziphathelene nobudala kuma-mouses aneminyaka, Cellular Reprogramming 26
- Abad et al. (2013), Ukuhlela kabusha in vivo kukhiqiza ama-teratomas namaseli we-iPS anezici ze-totipotency, Nature 502
- I-Parras et al. (2023), I-In vivo reprogramming iholela ekufeni okungemuva kokuqhathaniswa nokukhubazeka kwe-hepatic ne-intestinal, Nature Aging 3
- I-Life Biosciences (2026), FDA igunyaza ukufakwa kwe-IND ku-ER-100 kanye noudokotela wokuqala otholakele; irekhodi lokucwaninga NCT07290244
- Izimemezelo zenkampani: Altos Labs (2022), Retro Biosciences (2026), NewLimit (2026); kanye ne-MIT Technology Review (2023) ku-Retro Biosciences
- I-Jiang et al. (2025), ukubuyekezwa kwe-Interventions Testing Program, Journals of Gerontology A 80
- UHarrison nokunye (2014), Acarbose, 17-α-estradiol, ne-nordihydroguaiaretic acid zithuthukisa impilo yegundane ngokuyinhloko kubantu abadala, Aging Cell 13
- Strong et al. (2016), Isikhathi sokuphila eside kuma-peas abesifazane aphathwa nge-estrogenic agonist, i-antioxidant, i-α-glucosidase inhibitor noma i-Nrf2-inducer, Aging Cell 15
- Strong et al. (2008), Nordihydroguaiaretic acid ne-aspirin zithuthukisa impilo yezinhlanzi zesilisa ezingenazo i-genetic heterogeneous, Aging Cell 7
- U-Miller nokunye (2019), I-glycine supplementation ithuthukisa impilo yamazinyo esilisa nabesifazane, Aging Cell 18
- U-Miller nokunye (2020), I-Canagliflozin ithuthukisa isikhathi sokuphila kwezinhlanzi ezingenalutho zesilisa kodwa azikho izingulube, JCI Insight 5
- Strong et al. (2022), Inzuzo yokuphila kokuhlanganisa i-rapamycin kanye ne-acarbose kanye ne-captopril kuma-mouse ahlukene ngokwezenhlalo, Aging Cell 21
- I-Bannerster et al. (2014), Ngabe abantu abanesifo sikashukela sohlobo 2 bangaphila isikhathi eside kunalabo abangane?, Isifo sikashukela, Ukukhuluphala nokuguquka kwesimo sengqondo 16
- U-Barzilai nokunye (2016), Metformin njengethuluzi lokuvimbela ukukhuluphala, Cell Metabolism 23
- Amathuluzi (2022), Ukubuyekezwa kwemibiko yokuphila okunenzuzo esifo sikashukela sohlobo 2 esiphathwa nge-metformin uma kuqhathaniswa nokulawula ngaphandle kwesifo sikashukela, Izincwadi Eziphakathi Nezwe Zokwelapha 51
- I-Konopka et al. (2019), I-Metformin ivimbela ukuguquka kwe-mitochondrial ekuqeqesheni kokuzivocavoca okune-aerobic kubantu abadala, Aging Cell 18
- U-Walton nokunye (2019), Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults (MASTERS), Iseli Elidala 18
- U-Lincoff nokunye (2023), Semaglutide nemiphumela ye-cardiovascular ekukhulupheleni ngaphandle kwesifo sikashukela (SELECT), NEJM 389
- Xie, Choi noAl-Aly (2025), Ukudweba ukusebenza nokungcola kweGLP-1 receptor agonists, Imithi yemvelo 31
- I-Cummings et al. (2026), I-Oral semaglutide ekuqongeleleni isifo se-Alzheimer’s (evoke and evoke+), The Lancet 407
- I-Mattison et al. (2017), Ukuvimbela i-calorie kuthuthukisa impilo kanye nokuqhubeka kokuphila kwe-rhesus monkeys, Izokuxhumana zemvelo 8
- I-Kraus et al. (2019), iminyaka emi-2 yokuvimbela i-calorie kanye nengozi ye-cardiometabolic (CALERIE), *I-Lancet Diabetes & Endocrinology * 7
- Waziry et al. (2023), Imiphumela yokuvimbela i-calorie esikhathi eside kumazinga we-DNA methylation wokukhuluphala kwemvelo, Nature Aging 3
- I-Conboy et al. (2005), Ukuvuselelwa kweziseli ezineminyaka edlule zokuzalwa ngokugqwala indawo yokuphila encane, Nature 433
- I-Mehdipour et al. (2020), Ukuvuselelwa kwama-layers amathathu e-germ tissues ngokushintshana kwegazi elidala leplasma nge-saline-albumin, Aging 12
- I-Egerman et al. (2015), I-GDF11 ikhula ngobudala futhi ivimbela ukuvuselelwa kwamathambo eskeleton, Cell Metabolism 22
- I-Fuentealba et al. (2025), Ucwaningo lwe-multi-omics lubonisa ama-biomarkers asiza ukuvuselelwa kweminyaka yokuphila ngokuphendula ushintsho lweplasma lokuzivocavoca, Aging Cell 24
- I-Boada et al. (2020), I-randomized, elawulwa yiklinikhi yokuzama ukuguqulwa kweplasma ngokufaka i-albumin yesifo se-Alzheimer’s (AMBAR), Alzheimer’s & Dementia 16
- I-US Food and Drug Administration (2019), Isibikezelo esikhumbuza abakhiqizi ukuthi bangatholakali i-plasma yengane encane
- Horvath (2013), iminyaka ye-DNA methylation yama-tissue namaseli ajwayelekile, Genome Biology 14
- I-Hannum et al. (2013), I-genome-wide methylation profiles ibonisa ukubukeka okuningi kwezinga lokukhuluphala kwabantu, Molecular Cell 49
- I-Levine et al. (2018), I-biomarker ye-epigenetic yobudala bempilo nokuphila kahle (PhenoAge), Ubudala 10
- I-Lu et al. (2019), I-DNA methylation i-GrimAge ibikezela ngokuqinile isikhathi sokuphila nokunethezeka, Ubudala 11
- I-Belsky et al. (2022), DunedinPACE, i-DNA methylation biomarker yezinga lokukhuluphala, eLife 11
- I-Chen et al. (2016), Izibalo ze-DNA ezisekelwe ku-methylation zobudala bemvelo: ukuhlolwa kwe-meta ukubikezela isikhathi sokufa, Ubudala 8
- I-Higgins-Chen et al. (2022), Isinqumo sokusebenza sokuqinisa ukuthembeka kwe-epigenetic clocks, Nature Aging 2
- Inhlangano Yezempilo Yezwe (2020), Imiyalelo mayelana nomsebenzi wezocansi nokukhubazeka
- I-Jha et al. (2013), 21st-century hazards of smoking and benefits of cessation in the United States, NEJM 368
- SPRINT MIND Investigators (2019), Imiphumela yokulawulwa kwegazi eliqinile vs. elijwayelekile lokucindezeleka kobuhlungu benhliziyo, JAMA 321
- I-Struts et al. (2018), Ukuvimbela okuyinhloko kwezifo zenhliziyo nezitho zomoya nge-Mediterranean diet, NEJM 378
- U-Watson nokunye (2015), Recommended amount of sleep for a healthy adult, Sleep 38
- I-Holt-Lunstad et al. (2010), Ukuxhumana kwabantu kanye nengozi yokufa, PLOS Medicine 7
- U-Livingston nokunye (2024), Ukuvimbela, ukungeniswa, nokuphathwa kwe-Dementia: 2024 i-report ye-Lancet standing Commission, The Lancet 404
- I-Lin et al. (2023), Ukufaka isicelo sokulalela versus ukulawulwa kokufundisa impilo ukwehlisa ukuncipha kokucabanga (ACHIEVE), The Lancet 402
- Eyting et al. (2025), Izifundo ezijwayelekile mayelana nemiphumela yokwelashwa kwe-herpes zoster ku-dementia, Nature
- I-Paluch et al. (2022), Izinyawo zosuku nokufa okubangela konke: ukutadisha okwenziwe nge-meta kweqembu lezwekazi elingama-15, The Lancet Public Health 7
- I-Jousilahti et al. (2016), iminyaka engu-40 yeCHD yokufa nokuhlonishwa kwezinkomba zobungozi ekuhlalweni kokufa: iNorth Karelia Project experience, Global Heart 11
- I-Puska et al. (2016), Isizinda, izimiso, ukusetshenzisiwe, kanye nezingxoxo zobubanzi zephrojekthi yaseNorth Karelia, Global Heart 11
- I-Vartiainen et al. (2010), I-Finland, Incwadi yezwekazi ye-epidemiology 39
- I-Pell et al. (2008), Imithetho engekho emthethweni yokudlidliza kanye nokuhlinzwa emakhazeni ngenxa yesifo senhliziyo esibuhlungu, NEJM 359
- Ngandu et al. (2015), A 2 year multidomain intervention to prevent cognitive decline in at-risk elderly people (FINGER), The Lancet 385
- I-Hikichi et al. (2015), Imiphumela yezinhlelo zokungcebeleka ezikhuthaza ukuxhumana kwabantu abadala ngokunciphisa ukukhubazeka kwabo: ucwaningo lweJAGES Taketoyo, Journal of Epidemiology and Community Health 69
- I-United Nations, Department of Economic and Social Affairs, Population Division (2024), Izibalo Zomphakathi Womhlaba 2024: Isishwankathelo Semiphumela ne izithombe zedatha
- Sanderson noScherbov (2005), Isikhathi sokuphila esiphakathi nendawo esisha singakhuphuka njengoba inani labantu likhula, Nature 435
- Sanderson noScherbov (2010), Ukulinganisa kabusha ukukhuluphala, Isayensi 329
- Sanderson noScherbov (2015), Ukunyuka okukhawulelwe kokuphila kwabantu kungaholela ekukhululeni kwezigidi ezincane, PLOS ONE 10
- Inhlangano Yezempilo Yezwe, I-Global Health Observatory: ukulindeleka kokuphila nokulindeleka kokuphila okunempilo
- I-OECD Family Database, Iminyaka yamamama ngesikhathi sokuzalwa nobudala obuthile bokukhulisa
- Garrison (2026), Ngaphezu kokuzala: i-ovary njengendlela yokulawula impilo yabesifazane nokukhuluphala, PLOS Biology 24
- Ucwaningo lwe-VIBRANT lwe-rapamycin nesimo sesifo sokukhula kwesikhumba esincane, ClinicalTrials.gov NCT05836025
- GBD 2021 Fertility and Forecasting Collaborators (2024), Izibalo zesibalo sezingane eziphilayo emhlabeni jikelele ezizweni nezindawo ezingama-204, kusukela ngo-1950 kuya ku-2021, nezibalo ezilindelekile kuze kube ngu-2100, The Lancet 403
- Lutz, Skirbekk noTesta (2006), I-hypothesis yokugcoba okuphansi, Incwadi Yeminyaka Yocwaningo Lwezinhlanga
- Spears noGeruso (2025), Ngaphambi kweSpike: Umphakathi, Ukuthuthukiswa, kanye neNkathi yomuntu, Simon & Schuster
- Preston, Heuveline noGuillot (2001), Izakhiwo Zomphakathi: Ukulinganisa nokuhlela Imizamo Yomphakathi, Blackwell
- Myrskylä, Kohler noBillari (2009), Iziqukathi zokuthuthukiswa kokwehla kokukhulelwa, Nature 460
- Luci-Greulich noThevenon (2014), Ingaba ukuthuthukiswa komnotho ‘kubangela’ ukukhula kabusha kokukhulelwa?, Incwadi Yezwe lase-Europe 30
- Harttgen noVollmer (2014), Ukuguqulwa kobudlelwane bokukhula kwabantu nokukhulelwa?, Izakhiwo 51
- I-MIT Technology Review (2015), 2015 in biomedicine
- Imininingwane ye-charity kusuka ku- Charity Commission for England and Wales register kanye nesimo se-US esingasebenziyo kusuka ku- ProPublica Nonprofit Explorer